Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

AsCas12a Gene Editing of HBG1/2 Promoters with EDIT-301 Results in Rapid and Sustained Normalization of Hemoglobin and Increased Fetal Hemoglobin in Patients with Severe Sickle Cell Disease and Transfusion-Dependent Beta-Thalassemia

Rabi Hanna, Haydar Frangoul, Christopher McKinney, Luis Pineiro, Markus Mapara, Jignesh Dalal, Kai-Hsin Chang, Michael Jaskolka, Keunpyo Kim, Daphne L. Farrington, Maha Wally, Baisong Mei, Adebayo Lawal, Olubunmi O. Afonja, Mark C. Walters

Blood (2023) 142 (Supplement 1): 4996.

https://doi.org/10.1182/blood-2023-187397

Published: 2023

Journal Articles

PLX-R18 (Avoplacel), a Placental Expanded Mesenchymal-like Stromal Cell Therapy Shows Favorable Safety and Appears to Improve Incomplete Hematopoietic Recovery after Hematopoietic Cell Transplantation (HCT)

Hillard M Lazarus, Joseph P. McGuirk, Tsila Zuckerman, Leland Metheny, Luis Pineiro, Mark R. Litzow, Scott D. Rowley, Batia Avni, Roni Tamari, Michal Sheleg, Daniel Rothenstein, Nitsan Halevy, Jacob M. Rowe

Blood (2022) 140 (Supplement 1): 10447–10448.

https://doi.org/10.1182/blood-2022-169266

Published: 2022

Journal Articles

Final Analysis of a Phase 1b Study of Daratumumab in Combination with Carfilzomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma (RRMM)

Ajai Chari, MD, Sagar Lonial, Joaquin Martinez-Lopez, MD PhD, Maria-Victoria Mateos, Joan Bladé, MD PhD, Lotfi Benboubker, MD, Albert Oriol, Paula Rodriguez Otero, Luis Pineiro, Andrzej Jakubowiak, MD PhD, Yunsi Olyslager, Jianping Wang, Ivo Nnane, Jon Ukropec, PhD, Martin Shreeve, Ming Qi, MD PhD, Philippe Moreau, MD

Blood (2019) 134 (Supplement_1): 1876.

https://doi.org/10.1182/blood-2019-123539

Published: 2019

Journal Articles

Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma

Ajai Chari, Joaquín Martinez-Lopez, María-Victoria Mateos, Joan Bladé, Lotfi Benboubker, Albert Oriol, Bertrand Arnulf, Paula Rodriguez-Otero, Luis Pineiro, Andrzej Jakubowiak, Carla de Boer, Jianping Wang, Pamela L. Clemens, Jon Ukropec, Jordan Schecter, Sagar Lonial, Philippe Moreau

Blood (2019) 134 (5): 421–431.

https://doi.org/10.1182/blood.2019000722

Published: 2019

Journal Articles

Daratumumab in Combination with Carfilzomib and Dexamethasone in Patients (pts) with Relapsed Multiple Myeloma (MMY1001): An Open-Label, Phase 1b Study

Sagar Lonial, MD, Jesus F. San-Miguel, MD, Joaquín Martínez-Lopez, Maria-Victoria Mateos, MD, Joan Blade, Lotfi Benboubker, MD, Albert Oriol, MD, Bertrand Arnulf, Ajai Chari, Luis Pineiro, Kaida Wu, Jianping Wang, Parul Doshi, Jordan Schecter, Philippe Moreau, MDPhD

Blood (2017) 130 (Supplement 1): 1869.

https://doi.org/10.1182/blood.V130.Suppl_1.1869.1869

Published: 2017

Journal Articles

Preliminary Results of Phase II Trial of Clofarabine with Parenteral Busulfan (CLO/BU) Followed by Allogeneic Related or Unrelated Donor Transplantation for the Treatment of Hematologic Malignancies

Edward Agura, MD, R. Brian Berryman, MD, Luis Pineiro, MD, Mirjana Tadic-Ovcina, Ryan Woelfel, Estil A. Vance, MD, Joseph W. Fay, MD

Blood (2008) 112 (11): 4320.

https://doi.org/10.1182/blood.V112.11.4320.4320

Published: 2008

Journal Articles

Prevention of Graft-Versus-Host Disease (GVHD) with Tacrolimus after Allogeneic Grafting for Hematological Malignancies Following Sub-Myeloablative Conditioning.

Joseph Fay, MD, Giovanna Saracino, MS, Edward Agura, MD, Brian Berryman, MD, Luis Pineiro, MD, Estil Vance, MD

Blood (2006) 108 (11): 5321.

https://doi.org/10.1182/blood.V108.11.5321.5321

Published: 2006

Journal Articles

Phase II Study of Clofarabine and Cytosine Arabinoside in Adult Patients with Relapsed AML and in Elderly Patients with Untreated AML Who Are at High Risk of Anthracycline Toxicity.

Edward Agura, MD, R. Brian Berryman, MD, Laura Brougher, RN, Barry Cooper, MD, Andrew De Leon, RPh, Joseph Fay, MD, Houston Holmes, MD, Christopher Maisel, MD, Arturo Molina, MD, Luis Pineiro, MD, Giovanna Saracino, MD, Mirjana Tadic-Ovcina, MD, Estil Vance, MD

Blood (2006) 108 (11): 1951.

https://doi.org/10.1182/blood.V108.11.1951.1951

Published: 2006

NARROW

AsCas12a Gene Editing of HBG1/2 Promoters with EDIT-301 Results in Rapid and Sustained Normalization of Hemoglobin and Increased Fetal Hemoglobin in Patients with Severe Sickle Cell Disease and Transfusion-Dependent Beta-Thalassemia

PLX-R18 (Avoplacel), a Placental Expanded Mesenchymal-like Stromal Cell Therapy Shows Favorable Safety and Appears to Improve Incomplete Hematopoietic Recovery after Hematopoietic Cell Transplantation (HCT)

Final Analysis of a Phase 1b Study of Daratumumab in Combination with Carfilzomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma (RRMM)

Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma

Daratumumab in Combination with Carfilzomib and Dexamethasone in Patients (pts) with Relapsed Multiple Myeloma (MMY1001): An Open-Label, Phase 1b Study

Preliminary Results of Phase II Trial of Clofarabine with Parenteral Busulfan (CLO/BU) Followed by Allogeneic Related or Unrelated Donor Transplantation for the Treatment of Hematologic Malignancies

Prevention of Graft-Versus-Host Disease (GVHD) with Tacrolimus after Allogeneic Grafting for Hematological Malignancies Following Sub-Myeloablative Conditioning.

Phase II Study of Clofarabine and Cytosine Arabinoside in Adult Patients with Relapsed AML and in Elderly Patients with Untreated AML Who Are at High Risk of Anthracycline Toxicity.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only